Switching on kinases: oncogenic activation of BRAF and the PDGFR family.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15343278.
- Also identified by DOI 10.1038/nrc1434.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The cytoplasmic serine/threonine kinase BRAF and receptor tyrosine kinases of the platelet-derived growth factor receptor (PDGFR) family are frequently activated in cancer by mutations of an equivalent amino acid. Structural studies have provided important insights into why these very different kinases share similar oncogenic hot spots and why the PDGFR juxtamembrane region is also a frequent oncogenic target. This research has implications for other kinases that are mutated in human tumours and for the treatment of cancer using kinase inhibitors.
Medical subject headings
- Gene Expression Regulation, Neoplastic
- Proto-Oncogene Proteins c-raf
- Receptors, Platelet-Derived Growth Factor